Stay updated with breaking news from Yingli pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs ....
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development. ....
Shanghai Yingli Pharmaceuticals Ltd (Yingli Pharma), a clinical stage pharmaceutical company providing new therapies for cancer and metabolic diseases, announced today the topline data from a clinical trial sponsored by the company at the annual meeting of the European Hematology Association (EHA) being held June 9-17, 2021. ....
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib News provided by Share this article Share this article Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma Linperlisib has a differentiated and well manageable safety profile SHANGHAI, March 31, 2021 /PRNewswire/ Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma) announced topline results of a Phase II registration study of linperlisib, a PI3Kδ inhibitor, for the treatment of relapsed/refractory follicular lymphoma (FL). Linperlisib is a potent and highly selective oral PI3Kδ inhibitor that was developed for potentially more efficacious with a potentially more manageable and differentiated safety profile from other PI3Kδ class agents. The topline results of this sin ....
Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.